Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

By L. Honig, Bruno Vellas, M. Woodward, M. Boada, R. Bullock, M. Borrie, K. Hager, N. Andreasen, E. Scarpini, H. Liu-Seifert and 11 more. New England Journal of Medicine, 2018

862 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/096d61b05436d3936637b22cea56ce71a43aeb73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Huaqiu Chen
2. Yun Zhang
3. Keenan Sterling
4. Weihong Song
5. Ran Li

Citations in the corpus

• Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future (2023, background): “Although solanezumab was well tolerated in the participants, it was not able to show the significant therapeutic benefits to AD patients.(345,346) The failure may be due to the too low concentrations of the antibody reaching to the brain.”
• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, neutral): “A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”